A versatile supramolecular nanoadjuvant that activates NF-κB for cancer immunotherapy.

Although powerful adjuvants hold promise of vaccines for cancer immunotherapy, cumbersome preparation processes, elusive mechanisms and failure to induce T cell responses have largely limited their clinical translation. Due to their ease of synthesis, good biocompatibility and designable bioactivity, peptide derivatives-based supramolecular nanomaterials have attracted increasing interest in improving the immunogenicity of cancer vaccines.
Methods: Herein, we synthesized an NF-κB-activating supramolecular nanoadjuvant (3DSNA) that is prepared by pH-triggering self-assembly of a positively charged D-configurational peptide derivative. The immunostimulatory activity of 3DNSA was explored in vitro and in vivo.
Results: 3DSNA can strongly absorb the model antigen (ovalbumin, OVA) through electrostatic interaction. Then, 3DSNA promotes ingestion and cross-presentation of OVA, upregulation of costimulatory factors (CD80 and CD86) and secretion of proinflammatory cytokines (IL-6 and IL-12) by dendritic cells (DCs), accompanied by activation of the innate immune response (NF-κB signaling), resulting in long-term antigen-specific memory and effector CD8+ T cells response. When compared with conventional aluminum hydroxide adjuvant and the corresponding L-configurational supramolecular nanoadjuvant (3LSNA), 3DSNA-adjuvanted OVA (3DSNA+OVA) significantly prevents oncogenesis in naïve mice with a complete response rate of 60 %, restrains the tumor growth and prolongs the survival of melanoma-bearing mice.
Conclusion: These findings demonstrate that 3DSNA is a promising neo-adjuvant that enables various vaccines to be therapeutic for many important diseases including cancer.

Introduction

Successful cancer vaccines entail effective adjuvants to elicit a strong CD8+ T cell response 1-5. Current adjuvants approved by the FDA, such as aluminum hydroxide and emulsion MF59, can only induce humoral immune response with little or no CD8+ T cell response. Therefore, there is a great research interest in developing neo-adjuvants that can initiate a robust CD8+ T cell response for cancer immunotherapy. To address this problem, various types of adjuvants, including liposomes 6, 7, poly (lactic-co-glycolic acid) 8-10, Au nanoparticles 11 and silica materials 12, 13 have been explored to enhance antigen T-cells response. However, in the absence of immunomodulators (CpG, Poly (I:C), MPLA, etc.), few have the ability to coordinate optimal antigen presentation by antigen presenting cells (APC) with innate immune stimulation, which is critically important for inducing an effective CD8+ T cell response in the host. Moreover, the cumbersome preparation process of these formulations, involving chemical modification and an organic solvent, inevitably result in diminishing immunogenicity of antigens and the limitation of clinical application.

The supramolecular self-assembly process exists in nature and is closely related to the bioactivity of matter. Due to good manufacturing practices, biocompatibility and designable bioactivity, peptides have been used as building blocks to construct different supramolecular nanomaterials for drug delivery 14-17, cell cultures 17-20 and regenerative medicine 21, 22, etc 23-25. In the field of immunomodulation, pioneering studies have demonstrated that supramolecular self-assembled nanomaterials based on peptides as adjuvants could greatly evoke an immune response in the host 26-30. Recently, our studies 31, 32 have also shown that hydrogel formed by self-assembly of peptide derivatives with D-configuration amino acid could induce a strong antigen-specific humoral and cellular immune response, and the introduction of lysine (K) into the peptide derivative could further improve the immune response by promoting internalization of antigen by dendritic cells (DCs) 33. Despite this progress, current strategies require covalent conjugation of antigen to materials and a heating-cooling cycle or enzymatic trigger process. Additionally, the mechanism of immune stimulation remained indistinct. These shortcomings impede the advanced development of peptide derivatives as vaccine adjuvant.

Aiming to develop a minimalist and versatile vaccine adjuvant with a clear mechanism of immune activation, we designed a series of peptide derivates with different amino acid configurations and numbers of lysine (K), Ada-GDFDFDYGDKn-NH2 (n = 1, 2, 3, named as 1D, 2D 3D) and Ada-GFFYGKKK-NH2 (named as 3L) (Figure .1-Adamantaneacetic acid (Ada) and FF were chosen due to their excellent ability to self-assemble, our recent study indicated that hydrogels based on the tetrapeptide GFFY showed powerful capabilities to activate immune response and were promising vaccine adjuvants 31 and K was used to absorb antigen through the charge-charge interaction and improve antigen immunogenicity. As illustrated in Figure , compounds 2D, 3D and 3L could self-assemble into nanofibers at pH 7.4 in PBS buffer. Upon mixing with the model antigens (OVA), these nanofibers could immediately capture the protein by charge interaction. Compared to the supramolecular nanoadjuvant formed by 2D (2DSNA) and 3LSNA, 3DSNA, as a desirable cancer vaccine adjuvant, could not only load antigen with high efficiency but also provoke a strong innate and adaptive immune response. Therefore, the configuration and number of K were critical for building powerful supramolecular nanoadjuvants to enhance the antigen-specific CD8+ T cell response in a facile and highly effective manner.

Materials and Methods

Materials

Fmoc-amino acids were bought from GL Biochem (Shanghai, CHN). PE-tagged 25-D1.16 monoclonal antibody that recognizes the SIINFEKL-H-2Kb complex, PE-tagged anti-CD86, APC-tagged anti-CD80, anti-MCHⅡ-BV421, anti-CD86-APC, anti-IL-6-FITC, anti-IL-12-PE, Enzyme-linked immunosorbent assay (ELISA) kits for IL-6 and IL-12 were obtained from Biolegend (San Diego, USA). Alum adjuvant was acquired from Thermo Fisher (Waltham, USA). CpG adjuvant (ODN 1826) and chicken egg ovalbumin (OVA) were obtained from InvivoGen (Carlsbad, USA). Fluorescein and rhodamine-modified OVA were acquired from GenScript (Nanjing, CHN). Anti-CD8α tagged with APC, anti-IFN-γ tagged with FITC and anti-TNF-α tagged with PE were purchased from eBioscience (Waltham, USA). Chemical reagents and solvents were obtained from commercial sources without further purification.

Preparation of peptide derivates

Peptide derivates of Ada-GDFDFDYGDK-NH2, Ada-GDFDFDYGDKDK-NH2, Ada-GDFDFDYGDKDKDK-NH2, and Ada-GFFYGKKK-NH2 were prepared by standard Fmoc solid-phase peptide synthesis (SPPS), as previously described.33 In addition, the endotoxins of peptides < 1 EU mg-1 were measured by an endotoxin kit (Xiamen Bioendo Technology, CHN).

Preparation of nanofiber-adjuvants

Peptides (2 mg) were dissolved in 1 mL of 1x PBS buffer and 3 equiv. of Na2CO3 were used to adjust the pH value to 7.4. The solution was placed at room temperature for 12 h for molecular assembly.

Preparation of cancer vaccine formulated by nanofiber-adjuvants

Prefabrication nanofiber-adjuvant (1 mL) was mixed with 200 µg OVA power (endotoxin-free). The mixture stood at room temperature for 1 h to ensure sufficient absorption of the antigen.

Characterization of nanofiber-adjuvants and different vaccine formulations

The Zetasizer Nano ZS was used to measure the zeta potential of the nanoadjuvants and vaccine formulations at 25 °C in triplicate. Transmission electron microscope (TEM) was used to observe the morphology of the nanoadjuvants and vaccine formulations. For measurement of the loading efficiency of Rhod-OVA or protamine, vaccine formulated by nanofiber-adjuvant was centrifuged at 12000 rpm for 10 min; the optical density of supernatant was detected at 554 nm using a microplate reader for Rhod-OVA (Bio-RADiMarkTM, USA) or high performance liquid chromatogram (HPLC) for protamine.

In vitro release of OVA from vaccine formulations

Triple vaccine formulations (1 mL) were incubated at 37 °C with continuous shaking at 150 rpm. The formulations were centrifuged at 12000 rpm for 10 min at the predetermined time point. All supernatants were removed and fresh PBS buffer was added into the vaccine formulations. The optical density of the supernatant was detected at 554 nm using a microplate reader.

In vitro cytotoxicity of nanofiber-adjuvants

Biocompatibility was evaluated by the Cell Counting Kit-8 (CCK-8) assay. Splenocytes were extracted from mouse spleen following the procedure described in previous reports 33. In brief, at the pre-set time point, the spleen was collected and placed in RMPI1640 medium at 4 ℃. The spleen was gently ground in stainless steel mesh. The solution was then filtrated in 200 mesh gauze to acquire monodisperse cell suspension. Cells were then seeded in 96-well plates at a density of 104 cells/well with a total medium volume of 200 μL. After 24 h, the cells were incubated with fresh cell medium containing nanofiber-adjuvants with serial concentrations operated by double dilution for 72 h, followed by the addition of 10 μL of CCK-8 reagent per well. Four hours later, cell viability was evaluated by using a microplate reader to measure the optical density at 450 nm.

BMDCs assays in vitro

Bone marrow cells were obtained from the femur and tibia of C57BL/6J mice. X-vivo 15 medium (Lanza, MD, USA) containing GM-CSF (20 ng/mL) and IL-4 (10 ng/mL) was used to culture the cells for 6 days. The culturing medium was replaced every two days. On day 7, 1 mL of culture medium per well containing 1×106 BMDCs were seeded in 24-well plates; after 24 h, 50 μL formulated vaccines containing 100 µg nanofiber-adjuvants and 10 μg OVA, corresponding concentration of nanofiber-adjuvants or OVA were added to incubate for 24 h. Flow cytometry was performed to test BDMCs surface markers CD86 and CD80. ELISA kit and flow cytometry was carried out to determine the secreted IL-6 and IL-12 by BMDCs. Meanwhile, the BMDCs were collected to perform a western blot assay.

To evaluate the efficiency of nanoadjuvant on facilitating the internalization of antigen, 1 mL of culture medium per well containing 5×105 BMDCs were seeded in 24-well plates and were incubated with 12.5 μL of vaccines containing 2.5 μg FITC-OVA and 25 μg nanofiber-adjuvant for 30 mins.

To analyze the intracellular location of p-p65, the activating form of NF-κB, the BMDCs were treated with OVA, 3LSNA, 3LSNA+OVA, 3DSNA, 3DSNA+OVA for 24h and cells treated with PBS were used as controls. The cells were washed twice with PBS, permeabilized with Triton X-100 (0.1 %) and fixed with paraformaldehyde (4 %), successively. The cells were then blocked with 2% BSA for 2h. Afterwards, they were incubated at 4 ℃ overnight with rabbit anti-p-NF-κB (anti-p-p65) primary antibody (1:100 dilution, Cell Signal Technology). The cells were washed and incubated with goat FITC-conjugated anti-rabbit IgG (1:500 dilution) for 1h. After washing with PBS, the cells were stained with undiluted Fluoroshield Mounting Medium with DAPI and analyzed by confocal microscopy.

To measure the cross-presentation of antigen, BMDCs were treated with OVA, CpG+OVA, 3LSNA+OVA, 3DSNA+OVA and PBS as a control. After incubation for 24 h, BMDCs were washed with PBS for three times. 1×105 B3Z CD8C T hybridoma cells were incubated with 1×105 treated BMDCs for another 24h in a 96-well plate. The medium was then removed and 150 μL detection buffer containing 0.15 mM chlorophenol red-β-D-galactopyranoside, 0.1% Triton X-100, 9 mM MgCl2 and 100 μM mercaptoethanol was added. After incubation for 90 min at 37 ℃, the 96-well plate was measured at 570 nm by a microplate reader. After incubation with D1.16 monoclonal antibody and MCH-Ⅱ antibody for 30 min, the flow cytometry was carried out to measure the presentation.

Animal experiments

All work performed on animals was in accordance with and approved by the University Committee on Use and Care of Animals (UCUCA) at Sun Yat-sen and Jinan University. 6-8 weeks old female C57BL/6J mice were used for immune study and tumor-bearing model building. 100 μL vaccine (containing 10 μg OVA and 100 μg nanofiber-adjuvant) were s.c. injected at the inguen of mice at designated time points. To analyze the OVA-specific CD8+ T cells, peripheral blood mononuclear cells (PBMCs) from vaccinated mice were stained with PE-tagged SIINFEKL-MHC tetramer (MBL, Japan) and APC-tagged CD8α antibody. To measure the antigen-specific CTLs, the PBMCs were collected and seeded in a 24-well plate with 1 mL per well containing 1 × 106 cells; 100 ng SIINFEKL per well was added to restimulate the PBMCs for 12 h, which were then stained with anti-CD8α tagged with APC, anti-IFN-γ tagged with FITC and anti-TNF-α tagged with PE. Here, 2 × 105 B16-OVA cells were s.c. injected on the right flank of mice for tumor therapy and 4 × 105 B16-OVA cells were s.c. inoculated for tumor prophylaxis; the tumor volume was calculated by the following equation: tumor volume = length × width2 × 0.5. Animals were euthanized when the tumor volume reached more than 2000 mm3.

Statistical Analysis

Data are shown as the means ± SEM in all graphs depicting error bars. The statistical significance of differences between experimental groups was determined by one-way ANOVA and two-way ANOVA using GraphPad Prism 7; P values are indicated by *, # and &.

Results and Discussion

Optimization of the number of lysine (K) in peptide derivatives for vaccine adjuvants

To explore the influence of K on adjuvant potency, the ability of these peptide derivatives to self-assemble was measured. We found that 2 mg/mL 1D resulted in precipitation after adjusting the PBS buffer to pH 7.4, which is similar to physiological conditions (Figure , whereas 2 mg/mL 2D and 3D could self-assemble into homogeneously dispersed supramolecular nanofibers (Figure . However, there was no observed nanofibers when the pH value was adjusted to be 5.5 (Figure S10). When the number of K was 4, the peptide derivate could not self-assemble into nanofibers but nanoparticles (Figure . Then, the ability of adjuvants to load antigen and stimulate immune responses was evaluated in vitro, as shown in Figure . Compared with 2DSNA (96.1 and 93.6%, respectively), nearly 100 % (100.0 and 98.6 %, respectively) of the protein antigen was absorbed by 3DSNA at the weight ratio (OVA tagged with rhodamine, Rhod-OVA: DSNA) of 1:20 and 1:10. When the weight ratio was 1:5 (Rhod-OVA: DSNA), the loading efficiency of 3DSNA also slightly exceeded that of 2DSNA. The zeta-potential results showed that 3DSNA without loading OVA possessed more surface positive charge than 2DSNA, and the value of both decreased with increased proportion of OVA. Moreover, compared to 2DSNA, which exhibited a surface negative charge at a weight ratio (Rhod-OVA: DSNA) of 1:5, 3DSNA still had a slight surface positive charge (Figure . Both 3DSNA and 2DSNA could not trap the protein (protamine) with a positive charge (Figure . These results indicated that they interacted with the protein antigen through electrostatic absorption and therefore the loading efficiency of OVA by 3DSNA was higher than that by 2DSNA.

The stimulation of bone marrow dendritic cells (BMDCs) in vitro showed that both 2DSNA and 3DSNA significantly promoted the production and secretion of the proinflammatory cytokine IL-6 and IL-12 by BMDCs (Figure . More interestingly, 3DSNA significantly upregulated the expression of costimulatory CD80 and CD86 while 2DSNA failed to do so, implying that 3DSNA could induce a more potent immune response (Figure . These results indicated that the critical number of K in the peptide derivatives was three for endowing simultaneous formulation of vaccine and strong stimulation of immune response with high efficiency. Furthermore, 3L, used to study the effect of different configurations on adjuvant activity, could self-assemble into homogeneously disperse supramolecular nanofibers (3LSNA) (Figure , and then exhibited comparable results in terms of antigen loading and surface charge values (Figure and the same morphology of nanofiber (Figure as 3DSNA under the same prepared conditions. Therefore, 3DSNA and 3LSNA with good biocompatibility (Figure were leveraged as adjuvants to formulate antigen into cancer vaccine (3DSNA+OVA and 3LSNA+OVA) for further study.

Vaccine formulated by 3DSNA protected the host against tumorigenesis

Naïve mice were vaccinated by subcutaneous (s.c.) injection of 3DSNA+OVA, 3LSNA+OVA, free OVA (OVA) and Alum+OVA on day 0 and 7 (Figure . On day 28, melanoma cells expressing OVA (B16-OVA) were used to challenge the vaccinated mice to explore the immune-stimulating capability of different vaccine formulations. Figure 2B showed that all mice immunized with OVA, Alum+OVA and 3LSNA+OVA suffered tumorigenesis after day 13 post-inoculation of tumor cells. The percentage of tumor-free mice was 60 % on day 35 post-inoculation of tumor cells in the 3DSNA+OVA group, indicating vaccine adjuvanted by 3DSNA could effectively prevent the oncogenesis. On day 19 of post-injection of tumor cells, the average tumor volume only reached 49 mm3 in the 3DSNA+OVA group, which was significantly lower than that in the PBS (1571 mm3), OVA (1141 mm3), Alum+OVA (411 mm3), and 3LSNA+OVA (254 mm3) groups (Figure . After tumor cell challenge, the median survivals were 21, 21, 25 and 25 days in the PBS, OVA, Alum+OVA and 3LSNA+OVA groups, respectively, and it was encouraging that more than half (60 %) of the mice in the 3DSNA+OVA group still survived on day 35 (Figure . Since antitumor efficacy mainly depended on the cellular immune response, including cytotoxic T lymphocytes (CTLs), these results suggested that 3DNSA as an adjuvant possibly improved the cellular immune response to the OVA antigen.

Figure 2

A) Schematic of the immune study of naive mice. B) The percentage of vaccinated mice without tumorigenesis after challenge with B16-OVA cells on day 28; the data were analyzed by the log-rank test (** p < 0.01, 3DSNA+OVA compared with PBS, OVA, Alum+OVA; * p < 0.05, 3DSNA+OVA compared with 3LSNA+OVA, n = 5). C) Average tumor volume of vaccinated mice inoculated with B16-OVA cells on day 28; the data were analyzed by two-way ANOVA (**** p < 0.0001, 3DSNA+OVA compared with PBS, OVA, Alum+OVA and 3LSNA+OVA, n = 5). D) The representative pictures of tumor-bearing mice at day 18. E) The survival of vaccinated mice after inoculation with B16-OVA cells; the data were analyzed by the log-rank test (** p < 0.01, 3DSNA+OVA compared with PBS, OVA, Alum+OVA and 3LSNA+OVA, n = 5).

3DSNA exhibited potent immunostimulatory behavior through activation of NF-κB

DCs, as unique APCs, play a key role in priming naïve T cells. To explore the mechanism of 3DSNA as a vaccine adjuvant to augment immune response for abolishing oncogenesis, the effects of 3DSNA on the kinetics of antigen and activity of DCs were studied. First, the release of antigen (Rhod-OVA) from 3DSNA+OVA and 3LSNA+OVA was monitored at pH conditions similar to the site of s.c. injection. Figure showed that Rhod-OVA could be released from both nanofibers over 192 h. The sustained release of OVA from both nanofibers favored slow clearance and degradation in vivo, improving the immunogenicity to some extent.

It was reported that cellular uptake of biologics could be improved by a nanomaterial-mediated endocytosis mechanism, hence the influence of nanofibers on antigen uptake by DCs was further investigated. Compared with the free OVA, both 3DSNA and 3LSNA exhibited a 1.5-fold higher cellular internalization of antigen (OVA tagged with FITC, FITC-OVA) into BMDCs (Figure . The initiation of CD8+ T cell recognition of exogenous antigens demanded cross-presentation of internalized antigen. Figure showed that 3DSNA+OVA, but not free CpG plus free OVA (CpG+OVA) or 3LSNA+OVA, significantly improved the cross-presentation of antigen by DCs compared with free OVA, which was mainly attributed to the possibility that there was a quicker release of antigen from 3DSNA+OVA (average rate = ~10 % per day) compared to the release from 3LSNA+OVA (~5 %), and 3DSNA+OVA accelerated antigen cross-presentation 34. Costimulatory factors, CD86, and proinflammatory cytokines produced by DCs were considered as the second signal to activate the adaptive T cell response. The percentage of CD86-positive cells in BMDCs treated by 3DSNA+OVA was significantly higher than that in those treated with 3LSNA+OVA and 3LSNA, and slightly higher compared with free OVA and 3DSNA (Figure . 3DSNA and 3DSNA+OVA potently facilitated the production of proinflammatory cytokines IL-6 (Figure and IL-12 (Figure . Moreover, 3DSNA and 3DSNA+OVA enhanced the percentage of CD86+ IL-6+ (Figure and CD86+ IL-12+ (Figure cells among MCHⅡ+ cells. These improvements could augment CD8+ T cell activation and differentiate CD8+ T cells into cytotoxic T lymphocytes (CTLs) 35, 36.

Previous studies have reported that NF-κB signaling is a pivotal mediator in the regulation of the innate and adaptive immune response 37-39. The activity of this signal could promote antigen cross-presentation by MHC-I, costimulatory molecule upregulation, and proinflammatory cytokine production 40, 41. To determine the molecular mechanism of adjuvant activity, the NF-κB signal pathway was measured by western blot assay. Figure revealed that the levels of phosphorylation of p65 in the free OVA and 3LSNA groups were slightly higher than that in the PBS group, indicating that OVA and 3LSNA had a subtle influence on the activation of the NF-κB signal. The NF-κB signal was stronger in the BMDCs treated with 3LSNA+OVA than in those treated with OVA and 3LSNA, which probably resulted from their increased internalization of OVA. More importantly, 3DSNA and 3DSNA+OVA powerfully enhanced the phosphorylation of IKK-αβ, IkB-α and p65 in BMDCs compared with 3LSNA+OVA. Phosphorylation of IKK-αβ and IkB-α was slightly improved in the 3DSNA+OVA group, but p65 was not affected. The LSCM results showed that the fluorescence signals of p-p65 in nucleus from both 3DSNA and 3DSNA + OVA-treated BMDCs were stronger than those in other group (Figure . These results indicated that 3DSNA dominated activation of canonical NF-κB signaling and had a strong function in enhancing the adaptive T-cell immune response. Given its immunostimulatory competence as well as its cost-effectiveness, 3DSNA could be recognized as the optimal adjuvant with the smallest number of lysines in this system.

3DSNA-adjuvanted vaccine induced strong antigen-specific CD8+ CTLs

To further validate whether antigen-specific CTLs were induced, naïve mice were primed by s.c. vaccination with different formulations on day 0, boosted on day 7, and then antigen-specific (SIINFEKL tetramer-recognizing) CD8+ T cells and IFN-γ or TNF-α secreting CD8+ T cells from peripheral blood mononuclear cells (PBMCs) were measured at the designated time point (Figure . 3DSNA+OVA powerfully increased the frequency of SIINFEKL-specific CD8+ T cells. The percentage of SIINFEKL+ CD8+ T cells among all CD8+ T cells peaked by 3.7 % after 1 week post final immunization, which was greater by 1.5, 1.4 and 1.3-fold compared with the values in the OVA, Alum+OVA and 3LSNA+OVA groups, respectively (Figure . On day 28, when the tumor cells were inoculated (Figure , the frequency was higher in 3DSNA+OVA (0.8 %) group than in the OVA (0.4 %), Alum+OVA (0.5 %) or 3LSNA+OVA (0.6 %) groups (Figure . On day 28, the frequency of IFN-γ secretion by CD8+ T cells in the peripheral blood from mice treated with 3DSNA+OVA was 2.5-times higher than those treated with PBS. However, the frequency of IFN-γ+ CD8+ T cells in mice treated with Alum+OVA and 3LSNA+OVA were only approximately 1.5-times higher than PBS (Figure . 3DSNA+OVA also significantly increased the production of CD8+ T cells secreting TNF-α (Figure . These results implied that 3DSNA+OVA induced long-term strong antigen-specific memory and an effector CD8+ T-cells response, which was consistent with the strong efficacy of abrogating tumorigenesis (Figure and would make for the suppression of tumor advancement.

3DSNA-formulated cancer vaccine effectively inhibited tumor growth

Female C57BL/6J mice (6-8 weeks) were used to establish a B16-OVA tumor-bearing model for evaluating the effect of tested vaccine formulations on tumor therapy (Figure . The day when tumor cells were inoculated s.c. was defined as day 0. At day 7, 14 and 21, the surviving mice were immunized respectively. The tumor size was monitored every two or three days. We found that vaccination with 3DSNA+OVA significantly delayed the tumor progression, which only reached ~ 175 mm3 of tumor volume on day 21, whereas the tumor volume values were ~ 2158, 1460, 857 and 567 mm3 for the PBS, OVA, Alum+OVA and 3LSNA+OVA groups, respectively (Figure . As a result, the survival period for the tumor-bearing mice was substantially prolonged through vaccination with 3DSNA+OVA. Specifically, the median survival was 32.5 days for the 3DSNA+OVA group, which was an increase of approximately 67, 48, 38 and 25 % compared to the PBS, OVA, Alum+OVA and 3LSNA+OVA groups, respectively (Figure . This preferable anti-tumor activity could be accounted for the effector CD8+ T-cell response elicited by 3DSNA+OVA.

Conclusions

In this study, we have constructed a supramolecular nanoadjuvant (3DSNA) with good biocompatibility, which exhibited unique behaviors, including high antigen loading efficiency and improvement of the immune response against cancer vaccine. 3DNSA with nanofiber morphology is formed through self-assembly of a D-peptide derivative. This self-assembly is triggered by simply adjusting the pH, which involves no processes impairing antigen activity, such as chemical modification or the addition of exogenous enzyme or organic solvent. As a neo-adjuvant, it effectively binds with tumor antigen through simple electrostatic absorption, resulting in the increased expression of CD80 and CD86, production of IL-6 and IL-12, and cross-presentation of the SIINFEKL epitope by DCs in coordination with NF-κB activation. This delicate synchronization between cross-presentation of exogenous antigen and innate immunity stimulation initiates and develops naïve CD8+ T cells into antigen-specific CTLs secreting cytokines IFN-γ and TNF-α, which makes a vital difference in killing tumor cells (Figure . Although upstream targets of the NF-κB remains unknown, our study suggests that 3DSNA is an attractive candidate as adjuvant and suggest a general strategy in enhancing a range of subunit vaccines to elicit the CTL response for incurable diseases, including cancer.

Supplementary figures.

Click here for additional data file.